Elanco Animal Health Incorporated Common Stock (ELAN)
19.86
-1.78 (-8.23%)
NYSE· Last Trade: May 17th, 1:21 AM EDT
Since November 2025, Elanco has been in a holding pattern, floating around $21.39. The stock also fell short of the S&P 500’s 11.5% gain during that period. ...
Via StockStory · May 15, 2026
Elanco’s first quarter results were met with a positive market reaction, as management pointed to broad-based revenue growth across its pet health and farm a...
Via StockStory · May 13, 2026
Elanco Animal Health (NYSE:ELAN) raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerating demand for new products and continued debt reduction.
President and Chief Executive Officer Jef
Via MarketBeat · May 10, 2026
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.9% year on year to $1.37 bill...
Via StockStory · May 7, 2026
Elanco Animal Health (NYSE:ELAN) Soars After Strong Q1 Beat, Raises Full-Year Outlookchartmill.com
Via Chartmill · May 6, 2026
Elanco Animal Health Inc (NYSE:ELAN) Reports Strong Q4 Earnings Beat and Confirms 2026 Guidancechartmill.com
Via Chartmill · February 24, 2026
Elanco (ELAN) Q1 2026 Earnings Transcript
Via The Motley Fool · May 6, 2026
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ...
Via StockStory · May 6, 2026
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r...
Via StockStory · May 4, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...
Via StockStory · April 22, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Via StockStory · April 13, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · April 6, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via StockStory · March 27, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via StockStory · March 23, 2026
Elanco’s 26.6% return over the past six months has outpaced the S&P 500 by 23.6%, and its stock price has climbed to $23.47 per share. This was partly thanks...
Via StockStory · March 12, 2026
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Via StockStory · March 6, 2026
The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that hasn't plagued the American mainland in over half a century. As of March 2, 2026, federal authorities and state governments, led by Texas,
Via MarketMinute · March 2, 2026
Shares of animal health company Elanco (NYSE:ELAN)
jumped 8.2% in the morning session after the company reported fourth-quarter results that surpassed Wall Street's expectations, with investors focusing on strong current performance over a mixed outlook for 2026. For the quarter,
Via StockStory · February 24, 2026

Elanco (ELAN) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 24, 2026
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Animal health company Elanco (NYSE:ELAN)
will be reporting earnings this Tuesday before market open. Here’s what you need to know.
Via StockStory · February 22, 2026

This U.S. supplier serves construction and packaging markets with a diverse mix of cement, aggregates, wallboard, and paperboard.
Via The Motley Fool · February 14, 2026

FTI Consulting provides business advisory services worldwide, specializing in transformation, risk mitigation, and dispute resolution.
Via The Motley Fool · February 14, 2026

This enterprise software provider delivers cloud-based AI solutions for customer engagement, compliance, and financial crime prevention.
Via The Motley Fool · February 14, 2026
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026, the company finds itself at a pivotal crossroads. While it continues to dominate the multi-billion dollar markets for companion animal medicines [...]
Via Finterra · February 12, 2026